Biggest News Aggregation in the World
📰 From Baseline News

Page 2 - From Baseline News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from From Baseline. Real-time updates on events, politics, business and more.

BioArctic: Results from lecanemab confirmatory phase 3 Clarity AD study to be presented at 15th Clinical Trials on Alzheimer's Disease (CTAD) conference

BioArctic: Results from lecanemab confirmatory phase 3 Clarity AD study to be presented at 15th Clinical Trials on Alzheimer's Disease (CTAD) conference - read this article along with other careers information, tips and advice on BioSpace
Uppsala Lan San Francisco United States Oskar Bosson Takeshi Iwatsubo Abeta Protofibrils

EISAI TO PRESENT FULL FINDINGS FROM LECANEMAB CONFIRMATORY PHASE 3 CLINICAL TRIAL (CLARITY AD) AND OTHER ALZHEIMER'S DISEASE RESEARCH AT THE 15TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE

/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker findings from the companys...
University College New South Wales United States New Zealand San Francisco Haruo Naito

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

BioArctic: Lecanemab phase 3 Clarity AD study in early Alzheimer's disease meets primary and all key secondary endpoints with high statistical significance

STOCKHOLM, Sept. 28, 2022 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced positive topline results for the large global Phase 3 confirmatory Clarity
Uppsala Lan Oskar Bosson Gunilla Osswald Uppsala University Vp Communications National Institutes Of Health

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science